Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 29;10(5):1034.
doi: 10.3390/biomedicines10051034.

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review

Marleen Bouhuys  1 , Willem S Lexmond  1 , Patrick F van Rheenen  1
Affiliations
Review

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review

Marleen Bouhuys et al. Biomedicines. .

Abstract

Background: The long-term use of anti-TNF-α agents can lead to adverse effects, such as infections and immune-mediated cutaneous reactions. Whether de-escalation by dose reduction or interval lengthening reduces these adverse effects is uncertain. This systematic review aims to compare the incidence of infections and skin manifestations after anti-TNF-α dose de-escalation with standard dosing.

Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from inception to 14 January 2022. Randomized controlled trials (RCTs) and observational studies comparing anti-TNF-α de-escalation strategies with standard dosing among patients with inflammatory conditions, that report on infections, skin manifestations, or both, were included. The risk of bias was assessed with the revised Cochrane risk-of bias tool (RCTs) or the Newcastle-Ottawa scale (non-RCTs).

Results: Fourteen RCTs and six observational studies (or 2706 patients) were included. Eight RCTs had low risk of bias or some concerns. Four non-RCTs were of good methodological quality. The studies described patients with axial spondyloarthritis (8 studies, 780 patients), rheumatoid arthritis (7 studies, 1458 patients), psoriasis (3 studies, 332 patients), or inflammatory bowel disease (2 studies, 136 patients). De-escalation strategies included interval lengthening (12 studies, 1317 patients), dose reduction (6 studies, 1130 patients), or both (2 studies, 259 patients). Overall, the occurrence of infections and skin manifestations did not differ between standard treatment and de-escalation. The disappearance of infections or skin manifestations after de-escalation was only reported in two studies. The majority of studies focused on etanercept and adalimumab. Heterogeneity in reporting of infections and skin manifestations precluded meta-analysis.

Conclusion: We found that anti-TNF-α de-escalation does not reduce infections or skin reactions. A de-escalation strategy should not be recommended for the sole purpose of reducing drug-related adverse effects. The meticulous documentation of adverse effects is recommended to further address this question.

Registration: PROSPERO CRD42021252977.

Keywords: adalimumab; adverse effects; certolizumab pegol; dose reduction; etanercept; golimumab; infliximab; interval lengthening; tumor necrosis factor inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram of study selection.
Figure 2
Figure 2
Risk of bias of RCTs (revised Cochrane risk-of bias tool). * Scored for outcome of interest of this systematic review (i.e., the occurrence of new infections and/or skin manifestations, or the reduction and/or disappearance of infections and/or skin manifestations).
See this image and copyright information in PMC

References

    1. Levy R.A., Guzman R., Castañeda-Hernández G., Martinez-Vazquez M., Damian G., Cara C. Biology of anti-TNF agents in immune-mediated inflammatory diseases: Therapeutic implications. Immunotherapy. 2016;8:1427–1436. doi: 10.2217/imt-2016-0067. - DOI - PubMed
    1. Billmeier U., Dieterich W., Neurath M.F., Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J. Gastroenterol. 2016;22:9300–9313. doi: 10.3748/wjg.v22.i42.9300. - DOI - PMC - PubMed
    1. van Rheenen H., van Rheenen P.F. Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn’s Disease: A Systematic Review of Real-World Evidence Studies. Pediatr. Gastroenterol. Hepatol. Nutr. 2020;23:121–131. doi: 10.5223/pghn.2020.23.2.121. - DOI - PMC - PubMed
    1. Bressler B., Yarur A., Silverberg M.S., Bassel M., Bellaguarda E., Fourment C., Gatopoulou A., Karatzas P., Kopylov U., Michalopoulos G., et al. Vedolizumab and Anti-TNFα Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J. Crohns Colitis. 2021;15:1694–1706. doi: 10.1093/ecco-jcc/jjab058. - DOI - PMC - PubMed
    1. Smolen J.S., Aletaha D., Bijlsma J.W.J., Breedveld F.C., Boumpas D., Burmester G., Combe B., Cutolo M., De Wit M., Dougados M., et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann. Rheum. Dis. 2010;69:631–637. doi: 10.1136/ard.2009.123919. - DOI - PMC - PubMed

LinkOut - more resources